|
Search Term: " Balsam "
Does apple cider vinegar have health benefits?   
Date:
May 02, 2017 08:59 AM
Is there any apple cider vinegar in your pantry? If not, perhaps it is time to make this addition. Apple cider vinegar has an array of health benefits that are going to be yours when the vinegar is used on a regular basis. What are those health benefits? You've come to the right place to learn. DO not wait any longer to enjoy the massive health benefits that come with apple cider vinegar used in your life. Key Takeaways:
"If you are using apple cider or other vinegars as one part of an overall plan, combining it with a healthy diet, portion control and exercise, it might help, Drayer says. She suggested using balsamic vinegar on salads, in a 4:1 ratio with oil, or adding it to sauces for poultry and fish." Read more: http://www.cnn.com/2017/04/18/health/apple-cider-vinegar-uses/index.html
(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=4519) Myrrh Gum 
Date:
August 15, 2009 01:37 PM
Myrrh is the reddish-brown resinous material that comes from the dried sap of a number of trees. Primarily, it is obtained from the Commiphora myrrha, which is native to Yemen, Somalia, and the eastern parts of Ethiopia. Additionally, it comes from Commiphora gileadensis, which is native to Jordan. The sap of a number of other Commiphora and Balsamodendron species is also referred to as myrrh. Its name is most likely of Semitic origin. The quality of myrrh can be identified through the darkness and clarity of the resin. However, the best method of judging the resin’s quality is by feeling the stickiness of the freshly broken fragments. The scent of raw myrrh resin and its essential oil is sharp, pleasant, somewhat bitter, and be described as being stereotypically resinous. It produces a heavy, bitter smoke when it is burned. In ancient times, myrrh was valued as a fragrance and healing agent. Ancient Egyptain women used the burned myrrh to get rid of fleas in their homes. The Chinese used myrrh to heal wounds. They also used this herb for menstrual problems, bleeding, hemorrhoids, and ulcerated sores. Myrrh is often mentioned throughout the Bible. In the Old Testament it is referred to in the preparation of the holy ointment. In Esther, myrrh is used as a purification herb for women and it is a perfume in Psalm 45:8. This herb is a powerful antiseptic. Similar to Echinacea, it is a valuable cleansing and healing agent. Myrrh works on the stomach and colon to soothe and heal inflammation. This herb also provides vitality and strength to the digestive system. Myrrh stimulates the flow of blood to the capillaries. Additionally, it helps speed the healing of the mucus membranes. Among these include the gums, throat, stomach, and intestines. Myrrh can be applied to sore and it also works as an antiseptic. It can help promote menstruation, aid digestion, heal sinus problems, soothe inflammation, and speed the healing process. Research has verified the use of myrrh as an antiseptic. Sometimes, it is added to mouthwash and toothpaste. Myrrh has also been found to have mild astringent and antimicrobial properties. This herb contains silyamrin, which is able to protect the liver from chemical toxins and help increase liver function. The resin of the myrrh plant is used to provide alterative, antibiotic, antimicrobial, antiseptic, astringent, carminative, emmenagogue, expectorant, and stimulant properties. The primary nutrients found in this herb are chlorine, potassium, silicon, sodium, and zinc. Primarily, myrrh is extremely beneficial in treating asthma, bronchitis, colds, colitis, colon problems, cuts, emphysema, gangrene, gastric disorders, sore gums, hemorrhoids, herpes, hypoglycemia, indigestion, infection, lung disease, excessive mucus, pyorrhea, sinus problems, mouth sores, skin sores, tonsillitis, and toothaches. Additionally, this herb is very helpful in dealing with abrasions, arthritis, boils, breath odor, canker sores, coughs, diarrhea, diphtheria, eczema, gas, menstrual problems, nervous conditions, phlegm, rheumatism, scarlet fever, thyroid problems, tuberculosis, ulcers, wounds, and yeast infections. In order to obtain the best results when supplementing with this, or any herb, it is important to consult your health care provider before beginning any regimen while on medications. For more information on the many beneficial effects provided by myrrh, please feel free to consult a representative from your local health food store with questions.
(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=2056) Glycerylphosphorylcholine -- Supports Cognitive Function in AD ... 
Date:
May 24, 2005 09:52 AM
Cognitive Improvement in Mild to Moderate Alzheimer's Dementia After Treatment with the Acetylcholine Precursor Choline Alfoscerate: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Maria De Jesus Moreno Moreno, MD Instituto Nacional de la Senectud, Mexico City, Mexico
in both men and woman they consistently improved after 90 and 180 days versus baseline with adiministration of GPC three times a day, whereas in the placebo group they remained unchanged or worsened. Statistically significant differences were observed between treatments after 90 and 180 days. Keypoints: references: Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction, Science. 1982;217:408-414. 2. Larson EB, Kukull WA, Katzman RL. Cognitive impairment: Dementia and Alzheimer's disease. Annu Rev Public Health. 1992;13:431-449. 3. Hofman A, Rocca WA, Brayne C, et al, for the European Prevalence Research Group. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int d Epidemiol. 1991;20:736-748. 4. Blackwood W, Corsellis JAN, eds. Greenfield's Neuropathology. 3rd ed. London: Arnold; 1976. 5. Geldmacher DS. Cost-effective recognition and diagnosis of dementia. 5emin Neurol. 2002;22:63-70. 6. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459. 7. Perry EK. The cholinergic hypothesis--ten years on. Br Med Bull. 1986;42:63-69. 8. Giacobini E. From molecular structure to Alzheimer therapy. Jpn d Pharmacol. 1997;74:225-241. 9. Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int. 1998;32:413-419. 10. Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol. 1982;37:4-9. 11. Davis E, Emmerling MR, Jaen JC, et al. Therapeutic intervention in dementia. Crit Rev Neurobiol. 1993;7:41-83. 12. Amenta E Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropiate approaches? Mech Ageing Dev. 2001;122:2025-2040. 13. Sigala S, Imperato A, Rizzonelli P, et al. k-Alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eurd Pharmacol. 1992;211:351-358. 14. Govoni S, Battaini E Lucchi L, et al. Effects of alpha-glycerylphosphorylcholine in counteracting drug-induced amnesia: Through cholinergic and non-cholinergic mechanisms [in Italian]. Basi Raz Ter. 1991;21:75-78. 15. Canonico PL, Nicoletti F, Scapagnini U. Neurochemical and behavioral effects of alpha-glycerylphosphorylcholine [in Italian]. Basi Raz Te~ 1990;20: 53-54. 191 CLINICAL THERAPEUTICS ® 16. Parnetti L, Amenta E Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: An analysis of published clinical data. Mech Ageing Dev. 2001;122:2041-2055. 17. Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale. Gerontology. 1983;29:185-198. 18. Di Perri R, Coppola G, Ambrosio LA, et al. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19:330-341. 19. Frattola L, Piolti R, Bassi S, et al. Multicenter clinical comparison of the effects of choline alphoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. Curt Ther Res Clin Exp. 1991;49:683-693. 20. Muratorio A, Bonuccelli U, Nuti A, et al. A neurotropic approach to the treatment of multi-infarct dementia using L-c~-glycerylphosphorylcholine. Curt Ther Res Clin Exp. 1992;52:741-75l. 21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: APA; 1994. 22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. 23. Folstein ME Folstein SE. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198. 24. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399-401. 25. Hamilton M. A rating scale for depression.J Neurol Neurosurg Psychiatry. 1960;23:56-62. 26. Hamilton M. Development of a rating scale for primary depressive illness. BrJ Soc Clin Psych& 1967;6:278-296. 27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. AmJ Psychiatry. 1984;141:1356-1364. 28. Reisberg B, Ferris SH, De Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139. 29. National Institute of Mental Health. Clinical global impressions. In: Guy W, ed. ECDEU Assessment for Psychopharmacology. Revised edition. Rockville, Md: National Institute of Mental Health; 1976:217-222. 30. Burns A, Russell E, Page S. New drugs for Alzheimer's disease. Br J Psychiatry. 1999;174:476-479. 31. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159-169. 32. Knapp MJ, Knopman DS, Solomon PR, et al, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991. 192 M. Moreno 33. Lindstrom MJ, Bates DM. Newton-Rapshon algorithms for linear-mixed effects models for repeated measure data. J Am Stat Assoc. 1998;83:1014-1022. 34. Thai LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711. 35. Rogers SL, Friedhoff LT, for the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303. 36. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, for the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998; 158:1021-1031. 37. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and the safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65. 38. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318: 633-638. 39. Amenta E Bronzetti E, Del Valle M, Vega JA. Effects of alpha-glycerylphosphorylcholine in neuroanatomy of aging brain in experimental animals [in Italian]. Basi Raz Te~: 1990;20:31-38. Address correspondence to: Scientific Department, Italfarmaco SpA, via dei Lavoratori 54, 20092 Cinisello Balsamo, Milan, Italy.
(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=98) | ||||||||||||||||||||||||
